New trials, publications, preprints and grants on this target, month by month.
Trial
GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry
1 Jan 2027· NA · NOT_YET_RECRUITING· CTGOV
Trial
Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
1 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes
18 Nov 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publication
GLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubes.
4 Nov 2026· GeroScience· PUBMED
Publication
Discovery, optimization, and Phase 1 evaluation of a novel, orally available GLP-1R/GIPR dual agonist.
3 Nov 2026· Molecular metabolism· PUBMED
Publication
PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide.
2 Nov 2026· Molecular pharmaceutics· PUBMED
Trial
Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals
1 Nov 2026· NA · NOT_YET_RECRUITING· CTGOV
Trial
Mechanisms of Weight Loss: Tirzepatide vs Semaglutide
31 Oct 2026· PHASE4 · RECRUITING· CTGOV
Publication
Baseline depressive-symptom severity and divergent psychological trajectories during GIP and/or GLP-1 receptor agonist therapy: a prospective ecological momentary assessment study.
31 Oct 2026· Diabetology international· PUBMED
Publication
Baseline monocyte GIP receptor mRNA expression is associated with reductions in body weight and FIB-4 index after switching to tirzepatide in patients with type 2 diabetes.
31 Oct 2026· Diabetology international· PUBMED
Publication
Loss of GIPR in glutamatergic neurons does not impair acceleration of GLP-1-induced weight loss by GIPR antagonism.
31 Oct 2026· Molecular metabolism· PUBMED
Trial
Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
30 Oct 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity.
28 Oct 2026· Diabetes care· PUBMED
Publication
UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with type 2 diabetes: A multicenter, randomized phase 2 trial.
26 Oct 2026· Cell metabolism· PUBMED
Publication
Glucose-dependent insulinotropic polypeptide (GIP) signaling in visceral and subcutaneous adipose tissue: implications for obesity and metabolic disease-a narrative review with a structured literature search.
22 Oct 2026· Reviews in endocrine & metabolic disorders· PUBMED
Publication
Adverse oral effects of GLP-1 and GIP receptor agonists: a scoping review protocol.
20 Oct 2026· BMJ open· PUBMED
Publication
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review.
16 Oct 2026· Frontiers in endocrinology· PUBMED
Publication
Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis.
13 Oct 2026· The Journal of clinical endocrinology and metabolism· PUBMED
Publication
The Metabolic-Dermatologic Axis: GLP-1/GIP Agonists as Emerging Immunometabolic Therapies for Obesity-Associated Skin Disease.
12 Oct 2026· Clinics in dermatology· PUBMED
Publication
Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence.
9 Oct 2026· Pharmaceutics· PUBMED
Publication
Weight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic Review.
9 Oct 2026· Metabolites· PUBMED
Publication
UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial.
8 Oct 2026· Cell metabolism· PUBMED
Publication
Real-World Anthropometric Outcomes, Safety, and Use Patterns of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity and Glucose Metabolism Disorder: A Nationwide Multicentre Community Pharmacy Study.
8 Oct 2026· Healthcare (Basel, Switzerland)· PUBMED
Trial
Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide
7 Oct 2026· PHASE4 · RECRUITING· CTGOV
Publication
GLP-1 and Dual GLP-1/GIP Receptor Agonists in Lipedema: A Promising Therapeutic Option Requiring Rigorous Evaluation.
7 Oct 2026· International journal of dermatology· PUBMED
Publication
US Healthcare Professionals' Management of MASH and Knowledge of GLP-1, GIP, and Glucagon Receptor Agonists.
6 Oct 2026· Clinical and translational gastroenterology· PUBMED
Publication
Practical Considerations for the Use of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity: A Clinician-Oriented Guide.
5 Oct 2026· Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir· PUBMED
Publication
Bidirectional pharmacology of GIP receptor targeting in obesity: Historical foundations, mechanistic divergence, and translational boundaries.
5 Oct 2026· Peptides· PUBMED
Publication
Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
1 Oct 2026· Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition· PUBMED
Publication
GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity-Neurodegeneration Interface: A Narrative Review.
30 Sept 2026· International journal of molecular sciences· PUBMED